MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Common Stock (NQ:BIAF)

0.5850 -0.0434 (-6.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bioAffinity Technologies, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Are Pharma Stocks Harmful To Your Financial Health ? ↗
It seems time for the Securities and Exchange Commission to oversee stock advertising and consider a ban, or at least a danger warning label. 
Via Talk Markets
News headline image
bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q2 2024 ↗
bioAffinity Technologies just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Crude Oil Falls Sharply; Exxon Mobil Earnings Top Views ↗
 
Via Benzinga
News headline image
Nasdaq Tumbles 3%; US Economy Adds 114,000 Jobs In July ↗
 
Via Benzinga
Topics Economy
News headline image
Dow Dips Over 400 Points; Apple Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
News headline image
bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
News headline image
bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q1 2024 ↗
bioAffinity Technologies just reported results for the first quarter of 2024. 
Via InvestorPlace
News headline image
bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies News Update
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q4 2023 ↗
bioAffinity Technologies just reported results for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story